The FDA approved a label update with a new titration schedule for donanemab (Kisunla), an anti-amyloid drug approved to treat ...

A research team from Virginia Commonwealth University has found that a drug currently in clinical trials for brain disorders ...

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

There are currently no approved treatments in Canada that can slow the progression of Alzheimer's, only drugs to quiet ...

INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Neurons that die early in Alzheimer’s help drive brain waste removal. Treating this process sooner could change outcomes.

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The medicines are the first to slow the disease, which may give people extra ...

The annual review of clinical trials for Alzheimer’s highlights a growing number of active trials and drugs that could help ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...